Clinical trial
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial
NCT00731198 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial
- Lead sponsor
- Changhai Hospital
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2008
- Completion date
- July 31, 2009
- Enrollment
- 650 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.